IL-17A is a pro-inflammatory cytokine produced by T helper 17 (Th17) cells, playing a crucial role in immune responses, particularly in the defense against pathogens and in autoimmune diseases. It promotes the recruitment of neutrophils and the release of other cytokines, amplifying inflammation. Dysregulation of IL-17A signaling is associated with several chronic inflammatory conditions, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Targeting IL-17A or its receptor has shown therapeutic potential in treating these diseases by reducing inflammation and preventing tissue damage, making it an attractive target for immune-modulatory therapies.